Petr V. Krivorotko

Saint Petersburg, SPE, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.

Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 08, 2025

Comparison of outcomes of neoadjuvant chemotherapy in BRCA1- versus BRCA2-associated breast and ovarian cancers.

Comparison of outcomes of neoadjuvant chemotherapy in BRCA1- versus BRCA2-associated breast and ovarian cancers.

Journal: Exploration of targeted anti-tumor therapy

Published: February 08, 2025

A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer.

A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer.

Journal: Future oncology (London, England)

Published: September 16, 2024

Own experience of indocyanine green use in the diagnosis and treatment of breast cancer in N.N. Petrov NMRC of Oncology

Own experience of indocyanine green use in the diagnosis and treatment of breast cancer in N.N. Petrov NMRC of Oncology

Journal: Khirurgiia

Published: July 15, 2024

Tumor infiltrating lymphocytes (TILs) in triple negative breast cancer

Tumor infiltrating lymphocytes (TILs) in triple negative breast cancer

Journal: Arkhiv patologii

Published: June 17, 2024

Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.

Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.

Journal: ESMO open

Published: June 04, 2024

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.

Journal: The Lancet. Oncology

Published: March 14, 2024

Different approaches to target volume definition and boost delivery in surgery de-escalation clinical trial in breast cancer patients with pathological complete response.

Different approaches to target volume definition and boost delivery in surgery de-escalation clinical trial in breast cancer patients with pathological complete response.

Journal: Radiation oncology journal

Published: June 22, 2023

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.

Journal: The New England journal of medicine

Published: May 31, 2023

Resistance of breast cancer cells to paclitaxel is associated with low expressions of miRNA-186 and miRNA-7.

Resistance of breast cancer cells to paclitaxel is associated with low expressions of miRNA-186 and miRNA-7.

Journal: Cancer drug resistance (Alhambra, Calif.)

Published: March 21, 2023

Intraoperative Assessment of Breast Cancer Tissues after Breast-Conserving Surgery Based on Mapping the Attenuation Coefficients in 3D Cross-Polarization Optical Coherence Tomography.

Intraoperative Assessment of Breast Cancer Tissues after Breast-Conserving Surgery Based on Mapping the Attenuation Coefficients in 3D Cross-Polarization Optical Coherence Tomography.

Journal: Cancers

Published: March 15, 2023

Immunology and immunotherapy in breast cancer.

Immunology and immunotherapy in breast cancer.

Journal: Cancer biology & medicine

Published: June 09, 2022

Showing 1-12 of 41

Last Updated: 09/26/2026